Researcher profile

Duc Duy Nguyen

Duc Duy Nguyen contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 21 - EmergingVerification L1Unclaimed author
6works
0followers
5topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

6 published item(s)

preprint2023arXiv

Count What You Want: Exemplar Identification and Few-shot Counting of Human Actions in the Wild

This paper addresses the task of counting human actions of interest using sensor data from wearable devices. We propose a novel exemplar-based framework, allowing users to provide exemplars of the actions they want to count by vocalizing predefined sounds ''one'', ''two'', and ''three''. Our method first localizes temporal positions of these utterances from the audio sequence. These positions serve as the basis for identifying exemplars representing the action class of interest. A similarity map is then computed between the exemplars and the entire sensor data sequence, which is further fed into a density estimation module to generate a sequence of estimated density values. Summing these density values provides the final count. To develop and evaluate our approach, we introduce a diverse and realistic dataset consisting of real-world data from 37 subjects and 50 action categories, encompassing both sensor and audio data. The experiments on this dataset demonstrate the viability of the proposed method in counting instances of actions from new classes and subjects that were not part of the training data. On average, the discrepancy between the predicted count and the ground truth value is 7.47, significantly lower than the errors of the frequency-based and transformer-based methods. Our project, code and dataset can be found at https://github.com/cvlab-stonybrook/ExRAC.

preprint2023arXiv

Geometric Graph Learning with Extended Atom-Types Features for Protein-Ligand Binding Affinity Prediction

Understanding and accurately predicting protein-ligand binding affinity are essential in the drug design and discovery process. At present, machine learning-based methodologies are gaining popularity as a means of predicting binding affinity due to their efficiency and accuracy, as well as the increasing availability of structural and binding affinity data for protein-ligand complexes. In biomolecular studies, graph theory has been widely applied since graphs can be used to model molecules or molecular complexes in a natural manner. In the present work, we upgrade the graph-based learners for the study of protein-ligand interactions by integrating extensive atom types such as SYBYL and extended connectivity interactive features (ECIF) into multiscale weighted colored graphs (MWCG). By pairing with the gradient boosting decision tree (GBDT) machine learning algorithm, our approach results in two different methods, namely $^\text{sybyl}\text{GGL}$-Score and $^\text{ecif}\text{GGL}$-Score. Both of our models are extensively validated in their scoring power using three commonly used benchmark datasets in the drug design area, namely CASF-2007, CASF-2013, and CASF-2016. The performance of our best model $^\text{sybyl}\text{GGL}$-Score is compared with other state-of-the-art models in the binding affinity prediction for each benchmark. While both of our models achieve state-of-the-art results, the SYBYL atom-type model $^\text{sybyl}\text{GGL}$-Score outperforms other methods by a wide margin in all benchmarks.

preprint2022arXiv

EISA-Score: Element Interactive Surface Area Score for Protein-Ligand Binding Affinity Prediction

Molecular surface representations have been advertised as a great tool to study protein structure and functions, including protein-ligand binding affinity modeling. However, the conventional surface-area-based methods fail to deliver a competitive performance on the energy scoring tasks. The main reason is the lack of crucial physical and chemical interactions encoded in the molecular surface generations. We present novel molecular surface representations embedded in different scales of the element interactive manifolds featuring the dramatically dimensional reduction and accurately physical and biological properties encoders. Those low-dimensional surface-based descriptors are ready to be paired with any advanced machine learning algorithms to explore the essential structure-activity relationships that give rise to the element interactive surface area-based scoring functions (EISA-score). The newly developed EISA-score has outperformed many state-of-the-art models, including various well-established surface-related representations, in standard PDBbind benchmarks.

preprint2020arXiv

Repositioning of 8565 existing drugs for COVID-19

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected near 5 million people and led to over 0.3 million deaths. Currently, there is no specific anti-SARS-CoV-2 medication. New drug discovery typically takes more than ten years. Drug repositioning becomes one of the most feasible approaches for combating COVID-19. This work curates the largest available experimental dataset for SARS-CoV-2 or SARS-CoV main protease inhibitors. Based on this dataset, we develop validated machine learning models with relatively low root mean square error to screen 1553 FDA-approved drugs as well as other 7012 investigational or off-market drugs in DrugBank. We found that many existing drugs might be potentially potent to SARS-CoV-2. The druggability of many potent SARS-CoV-2 main protease inhibitors is analyzed. This work offers a foundation for further experimental studies of COVID-19 drug repositioning.

preprint2020arXiv

Review of COVID-19 Antibody Therapies

Under the global health emergency caused by coronavirus disease 2019 (COVID-19), efficient and specific therapies are urgently needed. Compared with traditional small-molecular drugs, antibody therapies are relatively easy to develop and as specific as vaccines in targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and thus attract much attention in the past few months. This work reviews seven existing antibodies for SARS-CoV-2 spike (S) protein with three-dimensional (3D) structures deposited in the Protein Data Bank. Five antibody structures associated with SARS-CoV are evaluated for their potential in neutralizing SARS-CoV-2. The interactions of these antibodies with the S protein receptor-binding domain (RBD) are compared with those of angiotensin-converting enzyme 2 (ACE2) and RBD complexes. Due to the orders of magnitude in the discrepancies of experimental binding affinities, we introduce topological data analysis (TDA), a variety of network models, and deep learning to analyze the binding strength and therapeutic potential of the aforementioned fourteen antibody-antigen complexes. The current COVID-19 antibody clinical trials, which are not limited to the S protein target, are also reviewed.

preprint2019arXiv

Are 2D fingerprints still valuable for drug discovery?

Recently, molecular fingerprints extracted from three-dimensional (3D) structures using advanced mathematics, such as algebraic topology, differential geometry, and graph theory have been paired with efficient machine learning, especially deep learning algorithms to outperform other methods in drug discovery applications and competitions. This raises the question of whether classical 2D fingerprints are still valuable in computer-aided drug discovery. This work considers 23 datasets associated with four typical problems, namely protein-ligand binding, toxicity, solubility and partition coefficient to assess the performance of eight 2D fingerprints. Advanced machine learning algorithms including random forest, gradient boosted decision tree, single-task deep neural network and multitask deep neural network are employed to construct efficient 2D-fingerprint based models. Additionally, appropriate consensus models are built to further enhance the performance of 2D-fingerprintbased methods. It is demonstrated that 2D-fingerprint-based models perform as well as the state-of-the-art 3D structure-based models for the predictions of toxicity, solubility, partition coefficient and protein-ligand binding affinity based on only ligand information. However, 3D structure-based models outperform 2D fingerprint-based methods in complex-based protein-ligand binding affinity predictions.